We are live on ! Find out more
DY

Dowling & Yahnke Portfolio holdings

AUM $2.15B
1-Year Est. Return 10.82%
This Fund
S&P 500
This Quarter Est. Return
+6.39%
1 Year Est. Return
-10.82%
3 Year Est. Return
+34.82%
5 Year Est. Return
+71.23%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$121M
Cap. Flow
+$60.5M
Cap. Flow %
5.47%
Top 10 Hldgs %
22.97%
Holding
307
New
21
Increased
95
Reduced
149
Closed
16

Top Buys

Rank Stock Value
1
VWOB icon
Vanguard Emerging Markets Government Bond ETF
VWOB
+$38.6M
2
VNQI icon
Vanguard Global ex-US Real Estate ETF
VNQI
+$12.4M
3
CATH icon
Global X S&P 500 Catholic Values ETF
CATH
+$3.35M
4
BNDX icon
Vanguard Total International Bond ETF
BNDX
+$2.4M
5
VNQ icon
Vanguard Real Estate ETF
VNQ
+$2.01M

Top Sells

Rank Stock Value
1
GE icon
GE Aerospace
GE
+$1.53M
2
MZTI
The Marzetti Company
MZTI
+$787K
3
XOM icon
ExxonMobil
XOM
+$601K
4
AGN
Allergan Inc
AGN
+$428K
5
XLB icon
State Street Materials Select Sector SPDR ETF
XLB
+$346K

Sector Composition

Rank Sector Weight
1 Miscellaneous 24.68%
2 Healthcare 12.86%
3 Financials 12.1%
4 Technology 12.09%
5 Consumer Staples 10.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIO icon
276
Bio-Rad Laboratories Class A
BIO
$10.4B
$221K 0.02%
927
-83
-8% -$20.1K
XLY icon
277
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$23.1B
$221K 0.02%
4,486
-722
-14% -$34K
BEN icon
278
Franklin Templeton
BEN
$17.6B
$218K 0.02%
5,028
-90
-2% -$3.9K
EW icon
279
Edwards Lifesciences
EW
$52B
$218K 0.02%
+5,808
New +$213K
ESL
280
DELISTED
Esterline Technologies
ESL
$217K 0.02%
+2,900
New +$238K
NVS icon
281
Novartis
NVS
$292B
$213K 0.02%
2,834
– –
DSL
282
DoubleLine Income Solutions Fund
DSL
$1.22B
– –
0
– –
APA icon
283
APA Corp
APA
$14.9B
$210K 0.02%
4,969
-985
-17% -$41.5K
RMD icon
284
ResMed
RMD
$34.7B
$208K 0.02%
+2,460
New +$203K
SGOL icon
285
abrdn Physical Gold Shares ETF
SGOL
$7.45B
$208K 0.02%
16,500
– –
AGN
286
DELISTED
Allergan plc
AGN
$205K 0.02%
+1,253
New +$225K
CHTR icon
287
Charter Communications
CHTR
$18.3B
$203K 0.02%
605
-14
-2% -$4.76K
DYSL
288
DELISTED
Dynasil Corporation of America
DYSL
$179K 0.02%
151,301
+5,000
+3% +$6.57K
FBRX icon
289
Forte Biosciences
FBRX
$169K 0.02%
+44
New +$176K
ATNM icon
290
Actinium Pharmaceuticals
ATNM
$31.7M
$15K ﹤0.01%
762
– –
RGLS
291
DELISTED
Regulus Therapeutics
RGLS
$12K ﹤0.01%
96
– –
ACWV icon
292
iShares MSCI Global Min Vol Factor ETF
ACWV
$3.4B
– –
-2,976
Closed -$242K
ADNT icon
293
Adient
ADNT
$1.47B
– –
-2,710
Closed -$228K
IMUX icon
294
Immunic
IMUX
$210M
– –
-125
Closed -$252K
TNDM icon
295
Tandem Diabetes Care
TNDM
$1.49B
– –
-1,757
Closed -$13K
WOR icon
296
Worthington Enterprises
WOR
$2.8B
– –
-8,360
Closed -$237K
WINT
297
DELISTED
Windtree Therapeutics Inc
WINT
– –
-20,003
Closed -$4K
LQMT
298
DELISTED
LIQUIDMETAL TECHNOLOGIES INC
LQMT
– –
-213,000
Closed -$83K
AGN
299
DELISTED
Allergan Inc
AGN
– –
-2,086
Closed -$428K
8 9 10 11
12

Similar funds

AC
Alleghany Corporation New York $2.21B AUM 10.5% 1-Year Est. Return
CCM
Covington Capital Management Los Angeles, California $2.32B AUM 12.18% 1-Year Est. Return
MIAN
Mariner Independent Advisor Network Overland Park, Kansas $2.33B AUM 14.85% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
SCA
Salient Capital Advisors Houston, Texas $1.74B AUM 12.95% 1-Year Est. Return
ACM
AlphaCrest Capital Management New York $1.64B AUM 23.4% 1-Year Est. Return
W
Wealthsimple Toronto, Ontario, Canada $2.69B AUM 18.39% 1-Year Est. Return

Dowling & Yahnke's Q4 2017 Portfolio in Review

As of Q4 2017, Dowling & Yahnke held 307 positions worth $1.11B, up 12% from $985M the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Dowling & Yahnke deployed $60.5M of net new capital in Q4 2017, opening 21 new positions and adding to 95 existing holdings. Its largest new stake was Vanguard Emerging Markets Government Bond ETF: 479,412 shares worth $38.5M.

By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was GE Aerospace, an estimated $1.53M trimmed.

  • Dowling & Yahnke's largest Q4 2017 buy was Vanguard Emerging Markets Government Bond ETF: 479,412 shares worth $38.5M.
  • Dowling & Yahnke added most to DexCom in Q4 2017, an estimated $1.82M increase.
  • Dowling & Yahnke's biggest Q4 2017 reduction was GE Aerospace, cutting an estimated $1.53M.
  • Dowling & Yahnke fully exited Allergan Inc in Q4 2017, selling an estimated $428K.
  • Dowling & Yahnke's ten largest holdings make up 23% of its $1.11B portfolio in Q4 2017.
  • Dowling & Yahnke opened 21 new positions and closed 16 in Q4 2017.
  • Dowling & Yahnke's portfolio value rose 12% quarter-over-quarter to $1.11B.

Based on Dowling & Yahnke's 13F filing for Q4 2017, filed 2 Feb 2018.